Maryam Imani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maryam Imani has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Farzaneh Fesahat
Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 shared publications Fateme Rahmani
Yazd Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences
2 shared publicationsFateme Zare
Yazd Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences
2 shared publicationsHossein Hadinedoushan
Yazd Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences
2 shared publicationsElahe Moji
Yazd Department of Biology University of Science and Art
1 shared publication- Fateme Sefid
Department of Molecular Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd 8916978477, Iran
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 783
Predictive value of miR-122-5p, miR-449a, miR-30b-5p, miR-34c-5p, miR-34b-5p in sperm recovery from testicular tissue of azoospermic infertile men
Background Infertility is a global health issue affecting approximately 15% of couples, with male factors contributing to nearly half of the cases. Azoospermia remains a major challenge in male infertility diagnosis and treatment. Current diagnostic methods rely on invasive techniques such as testicular biopsy, which carry risks of tissue damage. MicroRNAs (miRNAs), small non-coding RNAs involved in gene regulation, have emerged as potential non-invasive biomarkers for assessing spermatogenesis. This study aimed to evaluate the predictive value of miR-122-5p , miR-449a , miR-30b-5p , miR-34c-5p , and miR-34b-5p in sperm retrieval success from testicular tissue in azoospermic infertile men. Methods The azoospermic male patients were recruited, including a group with obstructive azoospermia (OA) and a group with non-obstructive azoospermia (NOA). Patients with a history of drug use, smoking, alcohol consumption, or systemic diseases were excluded. Testicular biopsy samples were collected using microdissection testicular sperm extraction (micro-TESE). The expression levels of selected miRNAs were assessed using quantitative real-time polymerase chain reaction (qRT-PCR), with normalization to SNORD-47. Statistical analysis was conducted using SPSS, with significance set at P < 0.05. Results The expression levels of miR-34b-5p , miR-449a , and miR-30b-5p were significantly lower in azoospermic patients compared to controls, suggesting their role in impaired spermatogenesis. Conversely, miR-34c-5p showed a slight upregulation in the case group, potentially indicating a compensatory mechanism in sperm maturation. miR-122-5p expression remained relatively unchanged between groups. Cycle threshold (Ct) and ΔCt analysis further validated these differences, emphasizing the potential role of miR-34b-5p , miR-449a , and miR-30b-5p in predicting sperm recovery from testicular tissue. Conclusion The differential expression of miR-34b-5p , miR-449a , and miR-30b-5p suggests their potential utility as biomarkers for predicting sperm retrieval success in azoospermic men, whereas miR-122-5p appears to have limited predictive value. Further studies with larger cohorts are required to validate these findings and explore their clinical applications in non-invasive male infertility diagnostics.
- 22 May 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 783
Open AccessPredictive value of miR-122-5p, miR-449a, miR-30b-5p, miR-34c-5p, miR-34b-5p in sperm recovery from testicular tissue of azoospermic infertile men
Background Infertility is a global health issue affecting approximately 15% of couples, with male factors contributing to nearly half of the cases. Azoospermia remains a major challenge in male infertility diagnosis and treatment. Current diagnostic methods rely on invasive techniques such as testicular biopsy, which carry risks of tissue damage. MicroRNAs (miRNAs), small non-coding RNAs involved in gene regulation, have emerged as potential non-invasive biomarkers for assessing spermatogenesis. This study aimed to evaluate the predictive value of miR-122-5p , miR-449a , miR-30b-5p , miR-34c-5p , and miR-34b-5p in sperm retrieval success from testicular tissue in azoospermic infertile men. Methods The azoospermic male patients were recruited, including a group with obstructive azoospermia (OA) and a group with non-obstructive azoospermia (NOA). Patients with a history of drug use, smoking, alcohol consumption, or systemic diseases were excluded. Testicular biopsy samples were collected using microdissection testicular sperm extraction (micro-TESE). The expression levels of selected miRNAs were assessed using quantitative real-time polymerase chain reaction (qRT-PCR), with normalization to SNORD-47. Statistical analysis was conducted using SPSS, with significance set at P < 0.05. Results The expression levels of miR-34b-5p , miR-449a , and miR-30b-5p were significantly lower in azoospermic patients compared to controls, suggesting their role in impaired spermatogenesis. Conversely, miR-34c-5p showed a slight upregulation in the case group, potentially indicating a compensatory mechanism in sperm maturation. miR-122-5p expression remained relatively unchanged between groups. Cycle threshold (Ct) and ΔCt analysis further validated these differences, emphasizing the potential role of miR-34b-5p , miR-449a , and miR-30b-5p in predicting sperm recovery from testicular tissue. Conclusion The differential expression of miR-34b-5p , miR-449a , and miR-30b-5p suggests their potential utility as biomarkers for predicting sperm retrieval success in azoospermic men, whereas miR-122-5p appears to have limited predictive value. Further studies with larger cohorts are required to validate these findings and explore their clinical applications in non-invasive male infertility diagnostics.
- Open Access
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , 4808235
Propofol and Glioblastoma Biology: A Narrative Review of Perioperative Clinical Evidence and PI3K/AKT‐Wnt‐miRNA, GABA‐A, and Immune‐Checkpoint Pathways
Glioblastoma multiforme (GBM) is the most prevalent and aggressive primary brain tumor, with a median survival of approximately 15 months despite current multimodal therapies. Recent clinical observations have suggested that the intravenous anesthetic propofol may be used to examine whether anesthetic agents can affect glioblastoma behavior. Several retrospective studies reported that, in surgical settings, propofol‐based total intravenous anesthesia (TIVA) is associated with reduced operative time, faster recovery, lower intraoperative blood loss, and decreased postoperative complications such as seizures and cerebral edema, benefits particularly evident in patients with low Karnofsky Performance Scores. However, current clinical evidence remains limited, and the reported effects on survival and recurrence are still inconsistent. Preclinical studies showed that propofol′s antitumor potential is mediated through modulation of the PI3K/AKT–Wnt–miRNA axis, reduction of oxidative stress, regulation of immune checkpoint molecules, and restoration of temozolomide sensitivity in resistant cells. However, some reports indicate that propofol may also induce stem‐like features via GABA‐A receptor activation, underscoring its complex and context‐dependent nature. This narrative review summarizes the current molecular and clinical evidence about propofol in GBM. Available laboratory and retrospective clinical studies indicate possible antitumor effects, but the present evidence does not support definitive clinical conclusions. Large prospective and multicenter studies are still needed to clarify the clinical role of propofol in patients with GBM.
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , 4808235
Open AccessPropofol and Glioblastoma Biology: A Narrative Review of Perioperative Clinical Evidence and PI3K/AKT‐Wnt‐miRNA, GABA‐A, and Immune‐Checkpoint Pathways
Glioblastoma multiforme (GBM) is the most prevalent and aggressive primary brain tumor, with a median survival of approximately 15 months despite current multimodal therapies. Recent clinical observations have suggested that the intravenous anesthetic propofol may be used to examine whether anesthetic agents can affect glioblastoma behavior. Several retrospective studies reported that, in surgical settings, propofol‐based total intravenous anesthesia (TIVA) is associated with reduced operative time, faster recovery, lower intraoperative blood loss, and decreased postoperative complications such as seizures and cerebral edema, benefits particularly evident in patients with low Karnofsky Performance Scores. However, current clinical evidence remains limited, and the reported effects on survival and recurrence are still inconsistent. Preclinical studies showed that propofol′s antitumor potential is mediated through modulation of the PI3K/AKT–Wnt–miRNA axis, reduction of oxidative stress, regulation of immune checkpoint molecules, and restoration of temozolomide sensitivity in resistant cells. However, some reports indicate that propofol may also induce stem‐like features via GABA‐A receptor activation, underscoring its complex and context‐dependent nature. This narrative review summarizes the current molecular and clinical evidence about propofol in GBM. Available laboratory and retrospective clinical studies indicate possible antitumor effects, but the present evidence does not support definitive clinical conclusions. Large prospective and multicenter studies are still needed to clarify the clinical role of propofol in patients with GBM.
- Open Access
- 6 October 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 763
Peripheral Blood Expression of MMPs and DNA Methylation-Related Genes in Women with Recurrent Spontaneous Abortion: A Case-Control Study
Background Recurrent spontaneous abortion (RSA) is one of the most common reproductive complications among women of childbearing age. Several factors—including genetic, anatomical, endocrine, infectious, environmental, and immunological causes—have been implicated in RSA. This study aimed to explore the potential association between RSA and the expression patterns of selected genes involved in critical biological processes related to pregnancy maintenance and miscarriage. Methods The relative expression levels of matrix metallopeptidase 2 (MMP2) , matrix metallopeptidase 9 (MMP9) , DNA methyltransferase 1 (DNMT1) , DNA methyltransferase 3 alpha (DNMT3A) , and methylenetetrahydrofolate reductase (MTHFR) were evaluated using peripheral blood samples from 30 women with a history of two or more spontaneous abortions (cases) and 30 age-matched non-pregnant women with no history of miscarriage and at least one successful pregnancy (controls). Results No significant differences in the mRNA expression levels of the target genes were observed between women with RSA and the control group. Conclusions Our findings suggest that peripheral blood gene expression profiles of MMP2, MMP9, DNMT1, DNMT3A , and MTHFR may not adequately reflect tissue-specific changes associated with RSA. Further investigations using relevant tissues, such as placental or decidual samples, are warranted to better understand the molecular mechanisms underlying RSA.
- 6 October 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 763
Open AccessPeripheral Blood Expression of MMPs and DNA Methylation-Related Genes in Women with Recurrent Spontaneous Abortion: A Case-Control Study
Background Recurrent spontaneous abortion (RSA) is one of the most common reproductive complications among women of childbearing age. Several factors—including genetic, anatomical, endocrine, infectious, environmental, and immunological causes—have been implicated in RSA. This study aimed to explore the potential association between RSA and the expression patterns of selected genes involved in critical biological processes related to pregnancy maintenance and miscarriage. Methods The relative expression levels of matrix metallopeptidase 2 (MMP2) , matrix metallopeptidase 9 (MMP9) , DNA methyltransferase 1 (DNMT1) , DNA methyltransferase 3 alpha (DNMT3A) , and methylenetetrahydrofolate reductase (MTHFR) were evaluated using peripheral blood samples from 30 women with a history of two or more spontaneous abortions (cases) and 30 age-matched non-pregnant women with no history of miscarriage and at least one successful pregnancy (controls). Results No significant differences in the mRNA expression levels of the target genes were observed between women with RSA and the control group. Conclusions Our findings suggest that peripheral blood gene expression profiles of MMP2, MMP9, DNMT1, DNMT3A , and MTHFR may not adequately reflect tissue-specific changes associated with RSA. Further investigations using relevant tissues, such as placental or decidual samples, are warranted to better understand the molecular mechanisms underlying RSA.
- Open Access
- 4 August 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 763
Peripheral Blood Expression of MMPs and DNA Methylation-Related Genes in Women with Recurrent Spontaneous Abortion: A Case-Control Study
Background Recurrent spontaneous abortion (RSA) is one of the most common reproductive complications among women of childbearing age. Several factors—including genetic, anatomical, endocrine, infectious, environmental, and immunological causes—have been implicated in RSA. This study aimed to explore the potential association between RSA and the expression patterns of selected genes involved in critical biological processes related to pregnancy maintenance and miscarriage. Methods The relative expression levels of matrix metallopeptidase 2 (MMP2) , matrix metallopeptidase 9 (MMP9) , DNA methyltransferase 1 (DNMT1) , DNA methyltransferase 3 alpha (DNMT3A) , and methylenetetrahydrofolate reductase (MTHFR) were evaluated using peripheral blood samples from 30 women with a history of two or more spontaneous abortions (cases) and 30 age-matched non-pregnant women with no history of miscarriage and at least one successful pregnancy (controls). Results No significant differences in the mRNA expression levels of the target genes were observed between women with RSA and the control group. Conclusions Our findings suggest that peripheral blood gene expression profiles of MMP2, MMP9, DNMT1, DNMT3A , and MTHFR may not adequately reflect tissue-specific changes associated with RSA. Further investigations using relevant tissues, such as placental or decidual samples, are warranted to better understand the molecular mechanisms underlying RSA.
- 4 August 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 763
Open AccessPeripheral Blood Expression of MMPs and DNA Methylation-Related Genes in Women with Recurrent Spontaneous Abortion: A Case-Control Study
Background Recurrent spontaneous abortion (RSA) is one of the most common reproductive complications among women of childbearing age. Several factors—including genetic, anatomical, endocrine, infectious, environmental, and immunological causes—have been implicated in RSA. This study aimed to explore the potential association between RSA and the expression patterns of selected genes involved in critical biological processes related to pregnancy maintenance and miscarriage. Methods The relative expression levels of matrix metallopeptidase 2 (MMP2) , matrix metallopeptidase 9 (MMP9) , DNA methyltransferase 1 (DNMT1) , DNA methyltransferase 3 alpha (DNMT3A) , and methylenetetrahydrofolate reductase (MTHFR) were evaluated using peripheral blood samples from 30 women with a history of two or more spontaneous abortions (cases) and 30 age-matched non-pregnant women with no history of miscarriage and at least one successful pregnancy (controls). Results No significant differences in the mRNA expression levels of the target genes were observed between women with RSA and the control group. Conclusions Our findings suggest that peripheral blood gene expression profiles of MMP2, MMP9, DNMT1, DNMT3A , and MTHFR may not adequately reflect tissue-specific changes associated with RSA. Further investigations using relevant tissues, such as placental or decidual samples, are warranted to better understand the molecular mechanisms underlying RSA.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Genetic Characterization of MODY in Iranian Families Using Multigenerational‐Based Whole‐Exome Sequencing Approach
Background: Maturity‐onset diabetes of the young (MODY), a common type of monogenic diabetes caused by a pathogenic variant in a single gene, is characterized by starting at an early age, autosomal dominant inheritance, and decreased secretion of insulin. Despite its clinical importance, its accurate diagnosis is challenging, and it is often misdiagnosed as other types of diabetes. Therefore, understanding the genetic basis of MODY can improve diagnostic accuracy. Methods: We initially performed genetic counseling for 2964 probands who visited the Yazd Diabetes Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, between 2018 and 2022. Clinical assessments and pedigree analyses were conducted for the accurate clinical diagnosis and management of diabetes. Among these, 11 probands with unknown types of diabetes who met specific criteria, including an inheritance pattern across at least three generations, at least seven affected individuals, and probands being under age 55, were selected for whole‐exome sequencing (WES). Finally, variants were verified by Sanger sequencing, pedigree analysis, and segregation analysis. Results: WES analysis detected pathogenic variants in two families, which confirmed MODY. Family 202 had a novel missense variant (GCK: c.484G > C; p.Gly162Arg; NM_000162.5). In Family 105, an extremely rare pathogenic frameshift variant (HNF1A: c.1136_1137del; p.Pro379ArgfsTer39; NM_000545.8) was identified. The segregation analyses of these variants also revealed that the variants largely co‐segregated with the diabetes phenotype in their respective families. Conclusion: This study clearly demonstrates the effectiveness of WES for the accurate identification of MODY subtypes in Iranian families. Moreover, these findings emphasize the need for further genetic screening programs in Iran to enhance MODY diagnosis, personalized treatment, and family genetic counseling.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Open AccessGenetic Characterization of MODY in Iranian Families Using Multigenerational‐Based Whole‐Exome Sequencing Approach
Background: Maturity‐onset diabetes of the young (MODY), a common type of monogenic diabetes caused by a pathogenic variant in a single gene, is characterized by starting at an early age, autosomal dominant inheritance, and decreased secretion of insulin. Despite its clinical importance, its accurate diagnosis is challenging, and it is often misdiagnosed as other types of diabetes. Therefore, understanding the genetic basis of MODY can improve diagnostic accuracy. Methods: We initially performed genetic counseling for 2964 probands who visited the Yazd Diabetes Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, between 2018 and 2022. Clinical assessments and pedigree analyses were conducted for the accurate clinical diagnosis and management of diabetes. Among these, 11 probands with unknown types of diabetes who met specific criteria, including an inheritance pattern across at least three generations, at least seven affected individuals, and probands being under age 55, were selected for whole‐exome sequencing (WES). Finally, variants were verified by Sanger sequencing, pedigree analysis, and segregation analysis. Results: WES analysis detected pathogenic variants in two families, which confirmed MODY. Family 202 had a novel missense variant (GCK: c.484G > C; p.Gly162Arg; NM_000162.5). In Family 105, an extremely rare pathogenic frameshift variant (HNF1A: c.1136_1137del; p.Pro379ArgfsTer39; NM_000545.8) was identified. The segregation analyses of these variants also revealed that the variants largely co‐segregated with the diabetes phenotype in their respective families. Conclusion: This study clearly demonstrates the effectiveness of WES for the accurate identification of MODY subtypes in Iranian families. Moreover, these findings emphasize the need for further genetic screening programs in Iran to enhance MODY diagnosis, personalized treatment, and family genetic counseling.